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Trypsin-fold proteases, the largest mammalian pro-
tease family, are classified by their primary substrate
specificity into one of three categories, trypsin-like,
chymotrypsin-like, and elastase-like, based on key
structural features of their active site. However, the
recently discovered neutrophil serine protease 4
(NSP4, also known as PRSS57) presents a paradox:
NSP4 exhibits a trypsin-like specificity for cleaving
substrates after arginine residues, but it bears
elastase-like specificity determining residues in the
active site. Here we show that NSP4 has a fully
occluded S1 pocket and that the substrate P1-argi-
nine adopts a noncanonical ‘‘up’’ conformation sta-
bilized by a solvent-exposed H-bond network. This
uncommon arrangement, conserved in all NSP4 or-
thologs, enables NSP4 to process substrates after
both arginine as well as post-translationally modified
arginine residues, such as methylarginine and citrul-
line. These findings establish a distinct paradigm for
substrate recognition by a trypsin-fold protease and
provide insights into the function of NSP4.
INTRODUCTION
The neutrophil serine proteases (NSPs)—neutrophil elastase
(NE), cathepsin G (CG), and proteinase 3 (PR3)—constitute a
family of trypsin-fold proteases that play critical roles in neutro-
phil-mediated clearance of invading microbes (Belaaouaj et al.,
1998; Reeves et al., 2002; Weinrauch et al., 2002) and in inflam-
mation (Pham, 2006). Recently, the serine protease PRSS57,
originally discovered by yeast signal trap screening and compu-
tational mining of human cDNA libraries (Clark et al., 2003), was
identified as the fourth NSP member and subsequently referred
to as neutrophil serine protease 4 (NSP4) (Perera et al., 2012).
Along with the other NSP members, NSP4 is stored in neutrophil
azurophilic granules (Perera et al., 2013). Remarkably, NSP4
is highly conserved from bony fish to human (Figure S1 available
online) and predates the evolutionary emergence of other NSPsStructure 22, 1333–13(Perera and Jenne, 2012; Perera et al., 2012). NSP4 is, therefore,
the ancestral NSP and likely plays fundamental roles in neutro-
phil biology.
The relatively broad substrate specificities of NE, CG, and PR3
are well understood based on the detailed knowledge of their
active site structures (Fujinaga et al., 1996; Hof et al., 1996; Navia
et al., 1989). NSP4, however, poses a conundrum in that it func-
tions as a trypsin-like protease by cleaving substrates strictly
after arginine residues (Perera et al., 2012, 2013), but its primary
sequence predicts a very different elastase-like active site with a
preference for small aliphatic amino acids. Among trypsin-fold
proteases, the active sites of trypsin, chymotrypsin, and elastase
help define the three major classes of substrate specificities at
the P1 position (Hedstrom, 2002) (Figure 1A). Trypsin-like prote-
ases, such as complement and coagulation factors, have a deep
S1 pocket to accommodate the long arginine side chain that is
stabilized by a salt bridge interaction with the highly conserved
D189 (chymotrypsinogen numbering). In contrast, elastase-like
proteases cannot accommodate a large arginine side chain
owing to their shallow S1 pocket. This raises the question of
how NSP4 is able to achieve its arginine specificity with an
apparent elastase-like S1 pocket (Figure 1B).
The findings presented in this study resolve the NSP4 paradox
and reveal why the classical trypsin-chymotrypsin-elastase
paradigm (Figure 1A), which has accurately predicted substrate
specificities of other trypsin-fold proteases, does not apply
to NSP4. We show here that NSP4 possesses a noncanonical
enzyme active site, thereby defining a highly distinctive para-
digm of substrate recognition by a trypsin-fold protease. In addi-
tion, our structural and biochemical characterizations of NSP4
yield important insights into the potential biological functions of
NSP4.
RESULTS
NSP4 Is an Arginine-Specific Protease with an Atypical
S1 Pocket
We used biochemical and structural methods to address the
question of how NSP4 is able to recognize a P1-arginine residue,
particularly in light of the F190 and S216 residues (chymotrypsin-
ogen numbering), which seem poised to obstruct the S1 pocket
(Figure 1B). First, we considered the possibility that NSP4 resi-
dues F190 and S216, situated on opposite sides of the opening40, September 2, 2014 ª2014 Elsevier Ltd All rights reserved 1333
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Figure 1. NSP4 Has an Elastase-like Active Site with Trypsin-like Arginine Specificity
(A) Schematic of trypsin, chymotrypsin, and neutrophil elastase S1 pockets and their interactions with the preferred P1 residue. Trypsin-like proteases have an
open acidic S1 pocket and form a salt bridge interaction between the substrate P1-arginine and the conserved D189 at the base of the S1 pocket (dashed lines).
Chymotrypsin-like proteases have an open hydrophobic pocket to accommodate bulky P1 residues. Elastase-like proteases have a shallow S1 pocket, formed
by residues protruding from the 216 and/or 190 positions, to accommodate only small aliphatic P1 residues.
(B) The S1 pocket on NSP4 is predicted to be shallow, and the question arises on how the substrate P1-arginine can be spatially accommodated on NSP4.
(C) Profiling of NSP4 P1 substrate specificity by use of a fluorogenic peptide substrate panel with different P1 residues treated with recombinant wild-type (WT) or
the inactive (S195A) NSP4 produced either from insect cells (BEVS), which was used in protein crystallography, or mammalian (CHO) cells, which was used in
enzyme activity assays.
(D) Cleavage of fluorogenic peptide by NSP4 S1 pocket mutants. Activity is measured as nanomolar product formed per second (nM/s). The enzyme kinetic
parameters are as follows:WT (CHO), kcat 0.136 ± 0.008 s
1, KM 13.8 ± 3.3 mM; F190A, kcat 0.014 ± 0.001 s
1, KM 14.3 ± 4.1 mM; S216G, kcat 0.012 ± 0.001 s
1, KM
11.8 ± 3.2 mM; and F190A/S216G, kcat 0.037 ± 0.002 s
1, KM 15.3 ± 3.1 mM. Data are represented as mean ± SD from three independent experiments, each
performed in duplicate.
See also Figure S1.
Structure
Structural Basis of NSP4 Substrate Specificityto the S1 pocket, might act as a movable gate to allow access to
the S1 pocket. If so, the substrate P1-arginine side chain could
be stabilized via a salt bridge interaction to the NSP4 D226 res-
idue (Figure 1B), a configuration that has been observed in com-
plement factor B (Xu et al., 2000) and an engineered variant of
trypsin (Perona et al., 1993). To test this hypothesis, we engi-
neered NSP4 variants having either a partially open (F190A or
S216G) or fully open (F190A:S216G) ‘‘gate,’’ all of which should
increase enzyme activity if our hypothesis was correct. To mea-
sure effects on NSP4 activity, we synthesized a fluorogenic
peptide that was specifically cleaved by NSP4 after arginine
1IRR3Y4SSYSFKK10 (Figure 1C). The results showed that the sin-
gle mutants (F190A or S216G) and the double mutant
F190A:S216G had approximately 10-fold and 4-fold reduced ac-
tivity (kcat/KM) compared to wild-type (Figure 1D). These results
did not support the movable gate hypothesis, but rather they
suggested that both F190 and S216 are critically important for
positioning the substrate to enable catalysis.
Crystal Structures of NSP4
To elucidate the structural basis of the P1-arginine recognition,
we determined the X-ray crystal structure of NSP4 with the
covalently bound substrate mimic D-Phe-L-Phe-L-Arg chloro-
methyl ketone (FFR-cmk) at 1.40 A˚ resolution. In addition, we1334 Structure 22, 1333–1340, September 2, 2014 ª2014 Elsevier Ltalso determined two nonisomorphous structures of NSP4 in
its apo-form at 2.55 A˚ and 2.70 A˚ resolutions (Table 1). All struc-
tures exhibit the double b-barrel and catalytic triad arrangement
characteristic of trypsin-fold serine proteases (Figure 2A). NSP4
also has an extended basic surface patch that may function to
localize NSP4 to negatively charged proteoglycans (Kolset and
Pejler, 2011) (Figure S2A). Consistent with this view, NSP4 ex-
hibited strong heparin binding in fluorescence polarization and
electrophoretic mobility shift assays (Figure S2B). Superposition
of the NSP4 structures also showed that the 99-loop (Figure 2A),
which forms the S2 and S4 substrate interaction sites, is labile
and may be implicated in NSP4 allosteric regulation as demon-
strated for other serine proteases (Debela et al., 2007; Ganesan
et al., 2009).
Structural Basis of NSP4 Arginine Specificity
Most importantly, the structural details of the active site re-
vealed a highly unusual mechanism by which the substrate
P1-arginine is recognized and concurrently explained the
NSP4 conundrum. The structures show that the canonical S1
pocket is nonexistent, as it is completely occluded by F190
and S216 (Figure 2B; Figure S3). As a result, D226 is inacces-
sible to the substrate but helps stabilize the occluded S1 pocket
by forming an H-bond with the F190 amide backbone andd All rights reserved
Table 1. Crystallography Data and Refinement Statistics
Data Collection Apo (Form 1) Apo (Form 2) FFR-cmk VLK-cmk
Space group P41 P63 P212121 P65
Cell dimensions
a, b, c (Ǻ) 70.4,70.4,150.0 86.6, 86.6, 69.4 55.0, 64.5, 68.4 89.7, 89.7, 108.6
a, b, g () 90, 90, 90 90, 90, 120 90, 90, 90 90, 90, 120
Resolution (Ǻ) 50–2.55 (2.64–2.55) 50–2.70 (2.80–2.70) 35.69–1.40 (1.45–1.40) 50.0–3.08 (3.19-3.08)
Rsymm 0.082 (0.494) 0.149 (0.683) 0.048 (0.765) 0.154 (0.810)
<I/sI> 14.1 (2.0) 12.8 (2.7) 34.3 (2.8) 12.5 (2.4)
Completeness (%) 99.3 (100) 99.8 (100) 93.8 (98.2) 99.2 (99.8)
Redundancy 3.8 (3.8) 6.2 (6.3) 7.0 (7.1) 6.6 (6.6)
Reflections measured 89,593 50,790 319,648 60,991
Unique reflections 23,577 8,192 45,664 9,241
Wilson B (A˚2) 62 52 18 81
X-ray source ALS 5.0.1 ALS 5.0.1 SSRL 7-1 ALS 5.0.1
Data reduction HKL2000 HKL2000 HKL2000 HKL2000
Refinement
Resolution (Ǻ) 50–2.55 50–2.70 50–1.40 50–3.08
Reflections (total) 23,565 8,192 45,530 9,240
Reflections in Rfree 1,203 802 2,276 423
Molecules per asymmetric unit 2 1 1 2
Rwork 0.197 0.187 0.192 0.185
Rfree 0.231 0.248 0.215 0.240
Mean B factor 54 33 20 62
Number TLS groups 8 4 4 8
No. atoms 3,775 1,850 2,136 3,710
Protein 3,572 1,795 1,811 3,562
Carbohydrate 76 38 38 98
Ligand 0 0 34 50
Solvent 127 17 253 0
Rmsds
Bond lengths (Ǻ) 0.009 0.008 0.008 0.009
Bond angles () 1.05 1.05 1.30 1.23
Ramachandran (%)
Preferred region 97.0 95.4 96.5 95.4
Values in parentheses are for highest-resolution shell.
Structure
Structural Basis of NSP4 Substrate Specificitycoordinating an extensive network of water molecules similar to
the comparably buried D226 found in neutrophil elastase (Navia
et al., 1989) and proteinase 3 (Fujinaga et al., 1996). The F190
and S216 side chains are highly ordered, consistent with the
absence of a ‘‘gate’’ mechanism; instead, residues F190 and
S216 form the floor of a shallow groove above the occluded
S1 pocket to accommodate the redirected arginine side chain
(Figure 2B). The arginine side chain movement from the canon-
ical ‘‘down’’ to the noncanonical ‘‘up’’ position in NSP4 is
accomplished by a rotation of the Cb-Cg bond (Chi2 angle) by
160 (Figure 3A). Otherwise, the catalytic triad, the oxyanion
hole, and the classical Ca trace of the FFR peptide, including
the antiparallel main chain interactions between the protease
214–216 residues and the substrate P1–P3 residues, are all pre-
served. The ‘‘up’’ conformation of P1-arginine is supported by
F190, which provides a hydrophobic platform that interactsStructure 22, 1333–13favorably with the aliphatic portion of the P1-arginine side chain.
In addition, the specificity for P1-arginine is conferred by a
network of H-bonds involving the guanidinium group, coordi-
nated by three H-bond acceptors—the S216 and S192 side
chain hydroxyl oxygen and the G217 backbone carbonyl oxy-
gen (Figure 3B). The importance of these H-bond interactions
for catalysis was examined by mutating the two H-bond accep-
tors S192 and S216. The single H-bond acceptor mutants
showed 10-fold reduced activity, whereas removal of both H-
bond acceptors (S192A:S216G) resulted in 20-fold reduction
(Figure 3C). Therefore, NSP4 has replaced the predominant
P1-arginine-stabilizing electrostatic interaction inside a typical
trypsin-like S1 pocket with a distinctive H-bond network situ-
ated on top of the occluded S1 pocket.
Despite NSP4’s poor activity toward P1-lysine substrates, we
were able to prepare a complex of NSP4 with the covalently40, September 2, 2014 ª2014 Elsevier Ltd All rights reserved 1335
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Figure 3. The P1 Arginine in the ‘‘Up’’ Conformation Is Stabilized by
an H-Bond Network
(A) Structural superposition of P1-arginine in NSP4 (magenta) and in factor VIIa
(yellow; PDB 1DAN).
(B) H-bond network around P1-arginine residue (magenta) in NSP4 (gray).
(C) Cleavage of fluorogenic peptide by NSP4 hydrogen bond mutants. The
enzyme kinetic parameters are as follows: WT (CHO), kcat 0.136 ± 0.008 s
1,
KM 13.8 ± 3.3 mM; S192A, kcat 0.019 ± 0.002 s
1, KM 7.7 ± 3.7 mM; S216G, kcat
0.012 ± 0.001 s1, KM 11.8 ± 3.2 mM; and S192A/S216G, kcat 0.006 ± 0.001
s1, KM 10.7 ± 3.9 mM. The data are represented as mean ± SD from three
independent experiments, each performed in duplicate.
See also Figure S4.
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Figure 2. NSP4 Features an Occluded S1 Pocket and Noncanonical
Interactions with P1 Arginine
(A) Superposition of NSP4 crystal structures: NSP4-apo form 1, NSP4-apo
form 2, NSP4:FFR-cmk, and NSP4:VLK-cmk. Helices are colored in blue,
strands in green, loops in orange, and disulfide bond in yellow. Asterisks
denote catalytic triad residues.
(B) Left: FFR-cmk (yellow sticks) bound to the canonical trypsin-like protease,
factor VIIa (gray), in a bird’s-eye view (top) and side view (bottom) of the S1
pocket; PDB 1DAN. The black dash lines represent salt bridge interaction
between D189 and P1-Arg. Right: FFR-cmk (magenta sticks) bound to NSP4
(gray) in a bird’s-eye view (top) and side view (bottom) of the S1 pocket.
See also Figures S2 and S3.
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Structural Basis of NSP4 Substrate Specificity
1336 Structure 22, 1333–1340, September 2, 2014 ª2014 Elsevier Ltbound lysine substrate mimic D-Val-L-Leu-L-Lys (VLK)-cmk
and obtain a crystal structure at 3.08 A˚ resolution. It shows that
the P1-lysine side chain adopts a conformation like that of P1-
arginine (Figure S4). However, unlike the longer P1-arginine side
chain, the shorter P1-lysine side chain cannot engage the full
complement of H-bonds as the P1-arginine, thereby explaining
the extremely poor cleavage after P1-lysine residues (Figure 1C).
NSP4 Can Process Substrates after Modified
Arginine Residues
An orthogonal way to validate the noncanonical NSP4 active site
is through the use of designed substrates with modified P1-argi-
nine derivatives such as methylarginine and citrulline (Figure 4).
Methylarginine is a methylated form of arginine and retains its
positive charge, whereas citrulline is the deiminated form of argi-
nine and becomes charge neutral. Methylarginine is resistant to
trypsin-like protease cleavage (Asami et al., 2012; Baldwin and
Carnegie, 1971) because the additional methyl group cannot
be spatially accommodated inside the canonical S1 pocket (Fig-
ure 4A, middle left). Similarly, citrulline is resistant to trypsin-like
protease cleavage (Proost et al., 2008) because the neutrald All rights reserved
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Figure 4. NSP4 Can Cleave Substrates after Modified P1 Arginine
Residues
(A) Schematic representation of P1-arginine, P1-methylarginine, and P1-
citrulline in the S1 pockets of canonical trypsin-like proteases (left) and NSP4
(right). Top: enclosed within the canonical S1 pocket, the P1-arginine is kept in
the ‘‘down’’ conformation and forms the critical salt bridge interaction. On the
NSP4 active site, the P1-arginine is held in the ‘‘up’’ conformation, hovering
above the occluded S1 pocket (dashed line), by a network of H-bonds. Middle:
P1-methylarginine is incompatible with the canonical S1 pocket due to steric
clash with the terminal methyl group (CH3 inmagenta), but it is accommodated
on the NSP4 active site due to solvent exposure of the terminal methyl group.
Bottom: P1-citrulline is incompatible with canonical S1 pocket due to its
inability to form the critical salt bridge interaction with the enzyme S1 pocket,
but it is accommodated on the NSP4 active site because all H-bond in-
teractions are still fulfilled. The red circular arrows on P1-arginine denote
rotational freedom about the Nε-Cz bond that would still yield productive H-
bond interactions if the bond was rotated 180. The long cyan arrows indicate
the direction of the H-bond from the H-bond donor to the H-bond acceptor.
(B) Rate of fluorogenic peptide cleavage with P1-arginine, P1-methylarginine,
and P1-citrulline (50 uM each) by the canonical trypsin-like protease, factor Xa
(FXa, 100 nM), or by recombinant NSP4 (50 nM) produced from mammalian
(CHO) or insect (BEVS) cells. The data are represented as mean ± SD from
three independent experiments, each performed in duplicate.
See also Figure S5.
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Structural Basis of NSP4 Substrate Specificity
Structure 22, 1333–13citrulline side chain can no longer form the critical salt bridge
interaction with the enzyme S1 pocket (Figure 4A, bottom left).
These structural limitations may not apply to NSP4 for the
following reasons. Because the P1-arginine guanidinium group
is partially solvent exposed on NSP4, we reasoned that NSP4
should accommodate modifications to the arginine guanidinium
group such as an extra methyl group (Figure 4A, middle right).
Similarly, while citrulline is charge neutral, it could still engage
the full complement of H-bonds, with the notable difference be-
ing the reversal for one of the H-bond donor and acceptor pairs,
where one of the two terminal imines (H-bond donor) on arginine
becomes an oxygen atom (H-bond acceptor) on citrulline (Fig-
ure 4A, bottom right).
Enzymatic assays with fluorogenic peptide substrates con-
firmed the atypical NSP4 active site (Figure 4B; Figure S5).
Consistent with our model, the arginine-specific trypsin-like pro-
tease factor Xa (FXa), which possesses a canonical S1 pocket
(Padmanabhan et al., 1993), could only cleave after the unmod-
ified P1-arginine peptide substrate; in stark contrast, NSP4 with
its distinctive active site cleaved after both unmodified and
modified P1-arginine residues. NSP4 cleaved after P1-methylar-
ginine and P1-citrulline with approximately half the activity of
unmodified P1-arginine peptide substrates. This is likely due to
the asymmetry of the NSP4 active site (Figures 2B and 3B).
The S192-facing side has more solvent exposure (less steric hin-
drance) andmore H-bond flexibility (S192 side chain can be both
an H-bond acceptor and donor) than the S216- and G217-facing
side, which is not solvent exposed and the G217 carbonyl oxy-
gen can serve only as an H-bond acceptor. As a result, while
P1-arginine has rotational freedom about the Nε-Cz bond (Fig-
ure 4A, top right, red circular arrows), the terminal methyl group
on P1-methylarginine and the terminal oxygen atom on P1-citrul-
line both need to be on the S192-facing side to avoid steric clash
and to maximize the H-bond network engagement, respectively.
The reduced rotational freedom about the Nε-Cz bond for P1-
methylarginine and P1-citrulline thereby likely accounts for their
reduced activity compared to the unmodified P1-arginine on
NSP4. Taken together, results from substituting key enzyme
active site residues (Figure 3) and substrate P1 residues (Figure 4)
provide a powerful approach to validate our structural finding,
underscore the highly unusual structural basis for NSP4 arginine
specificity, and highlight the flexibilities afforded by the NSP4
active site arrangement.
DISCUSSION
The herein described mechanism of P1-arginine recognition dis-
tinguishes NSP4 from all other arginine-specific proteases that
rely heavily on salt bridge interactions enclosed within a deep,
well-defined S1 pocket. In contrast, the arginine recognition by
NSP4 is independent of salt bridge interactions and relies on
two key structural features, both of which are essential and
distinctive to NSP4: the occluded S1 pocket and the H-bond ac-
ceptors around the P1-arginine guanidinium group. Most intrigu-
ingly, these hallmarks are preserved in NSP4 homologs, which
trace back to the bony fish that emerged early during vertebrate
evolution more than 400 million years ago. Specifically, the
S1 occluding residue F190 as well as the H-bond acceptors
S216 and S192 are found in all bony fish orthologs (Figure S1).40, September 2, 2014 ª2014 Elsevier Ltd All rights reserved 1337
Structure
Structural Basis of NSP4 Substrate SpecificityTherefore, the distinctive mechanism of arginine specificity
described here for human NSP4 is evolutionarily conserved.
Except for NSP4, all other trypsin-like proteases utilize the
canonical S1 pocket for interaction with the substrate P1-arginine
residue. This begs the question of why did nature ‘‘reinvent the
wheel’’ to engineer a new way of achieving arginine specificity in
a serine protease? One hypothesis is that this unusual active site
structure enables NSP4 to cleave substrates after post-transla-
tionally modified arginine residues, such as methylarginine and
citrulline, which are otherwise uncleavable by other trypsin-like
proteases. Furthermore, while no consensus sequence motifs
are known for citrullination, methylation of arginine residues often
occur at the consensus Arg-Gly or Arg-Gly-Gly sequence motifs
(Thandapani et al., 2013),whichmatch theNSP4 substrate prefer-
ence for glycine in the P10 position (Perera et al., 2012).
Arginine residues are modified into methylarginine and citrul-
line by two different families of enzymes, peptidyl arginine meth-
yltransfereases (Bedford and Clarke, 2009) and peptidyl arginine
deiminases (Vossenaar et al., 2003),which are expressedprimar-
ily within the cell. How would NSP4, a granule protease destined
for secretion, encounter these post-translationally arginine-
modified substrates that are predominantly found in the intracel-
lular space? While the precise mechanism for how a secreted
protease could have intracellular substrates is not fully resolved,
there is emerging evidence to suggest that NSPs do have impor-
tant intracellular substrates (Houghton et al., 2010; Lane and Ley,
2003; Papayannopoulos et al., 2010; Preston et al., 2002; Waka-
sugi and Schimmel, 1999). Similarly, the intracellular protease in-
hibitor serpinB1 (also known as leukocyte elastase inhibitor, LEI,
ormonocyte neutrophil elastase inhibitor,MNEI) is anestablished
physiological inhibitor of NSPs (Baumann et al., 2013; Cooley
et al., 2001; Yasumatsu et al., 2006). These data suggest that
NSPs, through an unknown mechanism, can reach their target
substrates in the cytoplasmic or nuclear compartments.
There are also prominent examples of proteins with modified
arginine residues found in the extracellular space. The process
of neutrophil extracellular traps (Brinkmann et al., 2004) would
release intracellular arginine-modified proteins to the extracel-
lular space (Khandpur et al., 2013; O’Donoghue et al., 2013;
Urban et al., 2009). In addition, many microbial proteins and
virulence factors as well as host defense proteins are known
to contain modified arginines, resulting from methylation (Fisk
and Read, 2011), citrullination (Marchant et al., 2013; Pyrc
et al., 2013), hydroxylation (Ge et al., 2012), phosphorylation
(Fuhrmann et al., 2009), or ADP-ribosylation (Deng and Barbieri,
2008; Stevens et al., 2009; Tsurumura et al., 2013). Perhapsmost
intriguingly, many chemokines have been shown to be citrulli-
nated (Loos et al., 2008; Mortier et al., 2010; Proost et al.,
2008; Struyf et al., 2009), which affect their proteolytic process-
ing, alter their receptor usage, and ultimately modulate their
potency. Given that NSPs are involved in the proteolytic activa-
tion of chemokines (Pham, 2006), the ability of NSP4 to poten-
tially process citrullinated chemokines could be an important
functional feature of NSP4 and explain why its distinctive enzyme
active site remained preserved through its long evolutionary his-
tory. More broadly, given our structural and biochemical data on
NSP4, future work on identifying NSP4 substrates should
consider the potential of NSP4 to process substrates with these
naturally modified arginine residues.1338 Structure 22, 1333–1340, September 2, 2014 ª2014 Elsevier LtFinally, given the critical importance of NSPs in many neutro-
phil-mediated inflammatory diseases (Korkmaz et al., 2010;
Pham, 2006), the distinctive active site of NSP4 raises the pos-
sibility that highly specific active site inhibitors against NSP4
may be achieved. A major obstacle in the design of protease
active site inhibitors is specificity, which is often difficult to
achieve due to the conserved active site topologies within a
protease family, in this case the extraordinarily large family of
trypsin-like proteases with arginine specificity. NSP4 is an
exception: its familiar trypsin-fold architecture belies a highly
distinctive active site, which should provide a high degree of
inhibitor specificity. Furthermore, while the lack of a typical
S1 pocket, and thus the absence of potential high affinity inter-
actions with inhibitor, may pose a challenge for achieving po-
tency with traditional small molecules, recent developments in
the use of macrocyclic compounds, as demonstrated by the
trypsin-fold hepatitis C virus NS3/4A protease inhibitors
(McCauley et al., 2010; Schiering et al., 2011), have shown
great promise in driving high affinity binding to relatively flat
enzyme active sites. Our understanding of this evolutionarily
ancient yet only recently discovered fourth NSP member is
just beginning to expand and the coming years hold the prom-
ise of exciting new insights into its downstream substrates and
biological functions.
EXPERIMENTAL PROCEDURES
NSP4 Protein Expression, Purification, and Crystallization
DNA encoding human NSP4 from Ile34 (Ile16 in chymotrypsinogen numbering)
to Ala283 was expressed in insect cells using baculovirus expression vector
systems (BEVS) with a N-terminal His6 tag and an enteropeptidase cleavage
site or in Chinese hamster ovarian (CHO) cells by transient expression with a
N-terminal FLAG tag. NSP4 was first purified by affinity and size exclusion
chromatography, activated with enteropeptidase, and subsequently purified
to homogeneity by ion exchange chromatography. NSP4 complexes were
made by mixing purified NSP4 with either D-Phe-L-Phe-L-Arg-cmk (FFR-
cmk) or with D-Val-L-Leu-L-Lys-cmk (VLK-cmk) and purified again by size
exclusion chromatography. Details are described in the Supplemental Exper-
imental Procedures.
NSP4 protein and NSP4:cmk-inhibitor complexes were concentrated to
10 mg/ml and crystallized by sitting drop vapor diffusion method at 19C.
NSP4:FFR-cmk crystallized in 20% polyethylene glycol monomethyl ether
(PEG MME) 2000, 0.1 M Tris (pH 8.5), and 0.2 M trimethylamine N-oxide.
Apo-NSP4 (form 1) crystallized in 15%–17% PEG-10,000, 0.1 M sodium
acetate (pH 4.4), and 0.1 M ammonium acetate. Apo-NSP4 (form 2) crystal-
lized in 22%–25% PEG 3350, 0.1 M Bis-Tris (pH 5.5), and 0.2 M NaCl.
NSP4:VLK-cmk crystallized in 20% PEG 3350 and 0.2 M potassium acetate,
with no additional buffer. Details are described in the Supplemental Experi-
mental Procedures.
Fluorogenic Peptide Cleavage Assay
Internally quenched fluorogenic peptide substrates were added to 50 nM
NSP4 or 100 nM Factor Xa (Enzyme Research Laboratories) in 50 mM Tris
(pH 8.0), 150 mM NaCl, and 2 mM CaCl2 at 37
C. Enzyme kinetic measure-
ments were fitted using the standard Michaelis-Menten kinetics model, and
a standard curve was generated to convert the rate of catalysis from the fluo-
rescence measurements (RFU/s) to nanomolar products formed per second
(nM/s). Details are described in the Supplemental Experimental Procedures.
ACCESSION NUMBERS
The Protein Data Bank (PDB) accession numbers for the atomic coordinates
and structure factors are as follows: NSP4 apo (form 1), 4Q7X; NSP4 apo
(form 2), 4Q7Y; NSP4:FFR-cmk, 4Q7Z; and NSP4:VLK-cmk, 4Q80.d All rights reserved
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